Publications by authors named "Morgan L MacBeth"
Rare melanoma subtypes, including acral, mucosal, and uveal melanomas, exhibit limited responses to immune checkpoint inhibitors (ICIs), yet the molecular mechanisms of immune resistance remain poorly defined. Here, we performed transcriptomic profiling of patient-derived xenografts (PDXs) and publicly available tumor datasets to systematically compare intratumoral gene expression across cutaneous and rare melanoma subtypes. We identified a convergent downregulation of innate immune pathogen sensing (IIPS) and type I interferon signaling pathways in rare melanomas compared to cutaneous, with lower expression also observed in anti-PD-1 non-responder tumors.
View Article and Find Full Text PDFArticle Synopsis
- Patients with acral and mucosal melanomas (A/M) have fewer treatment options and worse outcomes compared to those with cutaneous melanomas.
- The study analyzed 156 melanoma cases and discovered new genomic alterations in A/M melanomas that could be targeted for treatment.
- Key findings included unique alterations specific to A/M melanomas that respond to certain inhibitors, suggesting a need for tailored clinical testing and treatment strategies.
Subungual melanomas (SUM) arise beneath the nails of the hands and feet, and account for 0.7-3.5% of all malignant melanomas.
View Article and Find Full Text PDF